Surgalign Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Surgalign Holdings, Inc.
The European Medicines Agency says it does not have enough data to justify the approval of Olumiant for hospitalized COVID-19 patients. The marketing authorization application for another product, Reata’s Imbarkyd for chronic kidney disease, has also been withdrawn.
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
BioXpress Therapeutics and Abzena, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers. The companies plan to offer a “flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Artificial Intelligence
- Other Names / Subsidiaries
- Paradigm Spine, LLC
- Regeneration Technologies, Inc.
- Tutogen Medical, Inc.
- Pioneer Surgical Technology, Inc.
- RTI Biologics, Inc.
- Zyga Technology
- RTI Surgical, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.